ICU Medical (ICUI) Q4 2009 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2009 earnings summary
6 Nov, 2026Executive summary
FY09 delivered record revenue of $231.5M and net income of $26.6M; diluted EPS was $1.77.
Growth in custom products, new products and direct sales offset lower Hospira sales, while the critical care asset purchase shifted sales responsibility to direct channels.
Financial highlights
Revenue rose to $231.5M from $204.7M in 2008; net sales were $231.0M.
Operating income increased 21% to $38.0M; net income was $26.6M versus $24.3M, with diluted EPS of $1.77 versus $1.67.
Q4 revenue was $69.8M, gross profit $31.4M, net income $7.4M and diluted EPS $0.50.
Operating cash flow reached a record $48.6M; cash, cash equivalents and investment securities were $108.1M at year-end.
Outlook and guidance
FY10 gross margin estimated at ~43%, versus 47% in FY09; SG&A estimated at 27%-28% of revenue, versus 30% in FY09.
FY10 capital expenditures estimated at $17M-$20M, including ~$10M to complete the Slovakia plant.
FY10 U.S. CLAVE growth expected to be modest; critical care sales expected to increase, and custom infusion and oncology sales expected to continue rising.
Existing cash, investments and anticipated operating cash flow expected to fund operations for the next 12 months.
Latest events from ICU Medical
- Record revenue and cash flow, led by infusion and oncology, offset critical care pressure.ICUI
Q4 2011 - Custom and direct-channel growth lifted 2010 results, while Hospira concentration remains a key risk.ICUI
Q4 2010 - Record revenue and stronger margins, offset by lower earnings and critical care sales.ICUI
Q4 2012 - Normalized IV Solutions demand cut FY19 revenue, while cash and integration savings supported resilience.ICUI
Q4 2019 - Record FY16 growth funded an infusion transformation, with integration the near-term test.ICUI
Q4 2016 - Record FY15 performance, with growth led by Infusion and Oncology and diversification still critical.ICUI
Q4 2015 - HIS expanded the portfolio, but integration costs drove a FY2017 operating loss.ICUI
Q4 2017 - Integration neared completion as cash grew, but reported earnings absorbed heavy one-time charges.ICUI
Q4 2018 - Infusion Systems growth and record operating cash flow cushioned pandemic-driven weakness elsewhere.ICUI
Q4 2020